Spotlight on Non-Small Cell Lung Cancer
Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Project Oncology®Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
Project Oncology®NSCLC Care: Evaluating Durvalumab in the First-Line Setting
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Project Oncology®The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Project Oncology®Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Project Oncology®Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
- 03/21/2025
- 03/08/2025
- society.asco.org06/05/2024
- ajmc.com05/13/2024
- targetedonc.com02/16/2024
- uclahealth.org01/12/2024
society.asco.org